At the 4th CIIE in Shanghai, AstraZeneca joined hands with government, industry, academia, research institutes, medical institutions to usher in a new round of signings for promoting a healthcare ecosystem. The company and other parties will build a multi-level innovation ecosystem model in different fields by deepening the construction of the holistic disease management ecosystem, assisting the development of regional collaborative innovation, promoting the introduction of global innovative treatment solutions, supporting Chinese innovations to go global, and advancing internet+ healthcare.

Leveraging the spillover effect of the CIIE to promote global innovation

As the only "medical special zone" in the construction of Hainan’s Free Trade Port, Boao Lecheng pilot zone of international medical tourism, possesses favorable policies and location advantages, and has entered into partnership with many internationally renowned pharmaceutical manufacturers through previous CIIEs. At this year's CIIE, AstraZeneca joined hands with Boao Lecheng pilot zone of international medical tourism to jointly promote the accelerated introduction of innovative drugs for treatment of cancers and rare diseases, as well as to carry out research cooperation on the development model of Internet hospitals in China.

AstraZeneca, Hainan Boao Lecheng pilot zone of international medical tourism and Daiichi-Sankyo (China) Investment signed the "Hainan Strategic Cooperation Agreement on the Innovation of Antibody-Drug Conjugates" at the CIIE. The parties will promote pilot cooperation on innovative anti-tumor drugs, including DS8201, a new HER2-targeting antibody-drug conjugate and many other urgently needed imported drugs, as well as real-world policy advancement research and real-world data application experiments in the pilot zone with the Boao Medical Innovation Institute for breast cancer and other diseases to accelerate the introduction of innovative cancer drugs worldwide into China. They will combine the use of innovative drugs to provide innovative diagnostic and therapeutic solutions to meet the clinical needs of a wider range of Chinese patients, explore innovative commercial insurance and payment models in depth to improve the accessibility of innovative drugs and treatment methods for patients, so as to provide more professional and convenient healthcare services for Chinese patients.

AstraZeneca and the administration of Hainan Boao Lecheng pilot zone of international medical tourism also deepened their cooperation and signed the "Strategic Cooperation Agreement on Pioneering Steps in Use of Innovative Drugs for Rare Diseases," taking Selumetinib, the world's first targeted drug for neurofibromatosis type 1 as a pilot project in Hainan, further promoting the early use of innovative drugs for rare diseases, supporting the introduction of more innovative drugs for rare diseases and the establishment of rare disease diagnosis and treatment centers, actively implementing innovative payment schemes for rare diseases, and exploring real-world studies for rare diseases, to make drug for rare disease accessible both abroad and in China.

At the same time, the parties carried out a signing and launching ceremony for the pilot hospital cooperation on innovative drugs in Hainan to promote the introduction of new drugs to benefit patients as early as possible. In addition, the two parties have also joined hands with the International Economic Development Bureau of Hainan, the Hainan Health Commission, the China Hospital Development Institute of Shanghai Jiao Tong University, Huiyitianxia and VCbeat to launch the “Research on the Development Model of Internet Hospitals in China” for the development of the industry.

Due to the many opportunities and practical gains brought by the CIIE for exhibitors, the expo has become a preferred platform for the introduction of new products and technologies. At this year's CIIE, AstraZeneca announced a long-term strategic partnership with Kowa Pharmaceuticals (China) and was granted the exclusive rights to promote Kowa's Kalimate on the Chinese mainland.

Building sound ecosystem for healthcare industry

At this year's CIIE, AstraZeneca and Bio Island Company announced to co-build an innovation park to accelerate GIBI's efforts on creating a world-leading R&D center for biopharmaceuticals and biosecurity. In addition, more than 10 innovative enterprises and two partners joined the International Life Science Innovation Campus (iCampus) through its national satellites. With a number of industry-university-research cooperation projects launched, iCampus is expected to bring more wisdom power to life sciences through the cooperation of all sectors in the industry chain.

During the exhibition, AstraZeneca also joined hands with the municipal governments of Beijing, Guangzhou, Shenzhen, Chengdu, Hangzhou, Wuxi and Yixing to hold biopharmaceutical industry promotion and exchange sessions at the regional biopharmaceutical industry cooperation booth, providing partners with a comprehensive government-enterprise communication platform covering official policy interpretation, comprehensive industry introduction and round-the-clock resource matching and negotiation, thus further facilitating regional government-enterprise cooperation.

During the event, AstraZeneca has been laying emphasis on local innovation and strengthening cooperation with local biopharmaceutical companies. At the CIIE, AstraZeneca has signed a strategic cooperation agreement with Biocity, an innovative drug company focusing on the treatment of oncologyand immune diseases. The two companies will carry out strategic cooperation in R&D, medical and registration matters.

Creating multi-disease treatment ecosystem and helping industry establish standardized treatment system

In view of China's growing demand for chronic disease management and the gradual development of Chinese people's health management awareness, AstraZeneca welcomes more partners at this year's CIIE to step up the construction of an integrated ecosystem covering diagnosis and treatment of respiratory diseases, cancers, kidney diseases, and rare diseases.

For oncology and related specialty diseases, AstraZeneca, together with Shanghai Pharmaceutical Trade Association, released the phase outcome of the Blue Book entitled "Health Empowered by Integrated Ecology of Disease Management," which aims to establish the industry standard of integrated diagnosis and treatment, contribute to the improvement of medical service capacity and promote the construction of hospital management capacity, based on the patient-centered concept of integrated diagnosis and treatment and the continuous innovation, upgrading and improvement of products and services. AstraZeneca signed a strategic cooperation agreement with Biozon, Histo, AcornMed and AnchorDx to jointly promote standardized treatment and holistic disease management for urological cancer and gynecological diseases, as well as to build an integrated treatment ecosystem. AstraZeneca also signed a strategic cooperation agreement with LinkDoc to jointly build a lung cancer ecosystem to improve the level of lung cancer diagnosis and treatment for a greater number of lung cancer patients. As for the early screening and early diagnosis of patients with lung nodules, the company has invited high-quality companies of early diagnosis technology, such as SENMED, Deepwise, Dianei Technology, Geneseeq, Tantica, Singlera and AnchorDx, to participate in the establishment of a lung cancer early diagnosis alliance to promote the development and popularization of lung cancer early diagnosis technologies, so as to facilitate early diagnosis, early intervention and early treatment for patients. 

The event also included the signing of the AstraZeneca China and Siemens Healthineers, both parties will share high-quality resources to jointly create integrated doctor training courses in the field of oncology. The "Oncology Academic Season" will launch a series of courses on the Multi Disciplinary Team (MDT), providing full-course academic content for oncology physicians and promoting the improvement of China's overall level of cancer prevention and treatment.

Regarding the communication and cooperation platform provided by the CIIE, Leon Wang, Executive Vice President, International and China President of AstraZeneca, said, "For AstraZeneca, the CIIE is also an annual big moment belonging to us and our ecosystem partners. Through the CIIE, we have the opportunity to showcase to the whole world the innovative system for holistic disease management that we and our partners are building in China. In the future, focusing on different diseases and different patient needs, AstraZeneca will work together with our partners to establish a more standardized, specialized and intelligent integrated model of diagnosis and treatment, and make unremitting efforts to improve the quality of life of Chinese patients in the long run."

Facilitating convenience and accessibility of healthcare services with digital transformation

Following the national call for the development of Internet+ healthcare, more and more companies are entering the field of Internet, e-commerce and digital medical care. In order to develop a health management system that benefits all people around the needs of patients, AstraZeneca is actively engaged in the construction of a digital healthcare system with online and offline integration and assists the launch of a study on the development model of Internet hospitals in China.

AstraZeneca also held a kick-off meeting for the digital healthcare partnership ecosystem and entered into a strategic partnership with Ping An Health, TenCent Health and Baidu Health to jointly develop consumerized home-side digital healthcare applications, to breakthrough industry and geographical limitations, assisting the improvement of the accessibility of the medical and health system from the depth, and facilitating China's healthcare industry to strengthen the foundation of people's livelihood.

Regarding AstraZeneca's strategy to increase the digitalization of healthcare on the platform of the CIIE, Michael Lai, General Manager of AstraZeneca China, said, "The focus of digital healthcare is much more than making connections; it is more about using the Internet and other technological approaches to enhance the effectiveness of healthcare and the convenience of services, and expand the room for more imaginative applications, which is very valuable for the universal healthcare in China."

Breaking down barriers between companies and strengthening training of innovative talents

In addition to the introduction of products and technologies, AstraZeneca also paid great attention to the exchange of innovative talents at this year's CIIE, aiming to reach in-depth cooperation with universities and innovative enterprises through the platform. AstraZeneca signed a Memorandum of Understanding with the School of Life Sciences of Nanjing University to establish a talent workstation focusing on multi-faceted cooperation covering the transformation of scientific research results, the development of students' professional abilities, the recruitment of interns and graduates, as well as the establishment of scholarships. The iCampus has entered into a talent strategy entitled PLAN100 with Chic Health and Huijiu Learning to cultivate cross-border talents and seek innovative and collaborative development. PLAN100 as AstraZeneca's internal talent training program that has lasted for many years, will be upgraded to a new ecology this year to break down the barriers between companies and realize better talent exchange between companies.

Leon Wang commented, "The CIIE has been held for four years. We believe that it is getting bigger and better, giving us the opportunity to work with more partners to promote the continuous incubation and realization of innovations in China, to expand the influence of the healthcare innovation ecosystem at home and abroad, and to energize the dual cycle of medical and health innovation"

Related

Go to Forum >>0 Comment(s)